Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Dow
Covington
Deloitte
Fuji
QuintilesIMS
Medtronic
Baxter
Cantor Fitzgerald

Generated: July 18, 2018

DrugPatentWatch Database Preview

Trimetrexate glucuronate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for trimetrexate glucuronate and what is the scope of trimetrexate glucuronate patent protection?

Trimetrexate glucuronate
is the generic ingredient in one branded drug marketed by Medimmune Oncology and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Trimetrexate glucuronate has six patent family members in six countries.

There is one drug master file entry for trimetrexate glucuronate.
Summary for trimetrexate glucuronate
Medical Subject Heading (MeSH) Categories for trimetrexate glucuronate
Synonyms for trimetrexate glucuronate
2, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-,mono-D-glucuronate
2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline mono-D-glucuronate
2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-, mono-D-glucuronate
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxo-hexanoic acid
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 2,3,4,5-tetrahydroxy-6-oxohexanoic acid
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediaminetrihydrochloride
5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine D-glucuronate
6-(((3,4,5-Trimethoxyphenyl)amino)methyl)-5-methyl-2,4-quinazolinediamine glucuronate
82952-64-5
AC1L1I26
AC1L7KE0
AN-36082
C19H23N5O3.C6H10O7
CA012032
CHEMBL2007423
D-Glucuronic acid, compd. with 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine (1:1)
D-Glucuronic acid,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine (1:1)
D06239
DRG-0183
DTXSID90273968
L137U4A79K
LS-71744
NCI60_003150
Neuro_000185
Neutrexin (TN)
NSC 352122
NSC-352122
SCHEMBL3635
Trimetrexate D-glucuronate
Trimetrexate glucuronate (USAN)
Trimetrexate glucuronate [USAN]
trimetrexate glucuronic acid combination
Trimetrexate glucuronic acid salt
UNII-L137U4A79K

US Patents and Regulatory Information for trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for trimetrexate glucuronate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,258,952 Thermally stable trimetrexates and processes for producing the same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Baxter
Cerilliant
Fish and Richardson
Accenture
Farmers Insurance
Healthtrust
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.